Who
Matthew E. Korenberg
CFO, Treasurer
Company insider
Files Form 4 as: CFO, Treasurer, Palvella Therapeutics; Director, Lifecore Biomedical; President & COO, Ligand Pharmaceuticals; Director, FF EAI Robotics Ecosystem.
In numbers
- Trades disclosed
- 129
- Buys
- 1
- Sells
- 10
- Bought
- $43K
- Sold
- $12.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 6 Aug 2015
- Last trade
- 12 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 16 Jun 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $14K1,000 at $13.60 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,000 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $14K1,000 at $13.60 | filing |
| 4 Jun 2026filed 5 Jun 2026 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Code A | —25,907 | filing |
| 4 Jun 2026filed 5 Jun 2026 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Code A | —25,907 | filing |
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,123 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,123 at $0.00 | filing |
| 15 Jul 2025filed 17 Jul 2025 | LFCR Lifecore BiomedicalBiotechnology | SEC FORM 4 Code A | —19,506 | filing |
| 5 Feb 2025filed 10 Feb 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,373 at $0.00 | filing |
| 5 Feb 2025filed 10 Feb 2025 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —123,559 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —167,100 at $0.00 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —395 at $0.00 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,377 at $0.00 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $20K395 at $49.99 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $495K9,377 at $52.84 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $248K2,481 at $100.05 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $720K7,090 at $101.61 | filing |
| 23 Sep 2024filed 24 Sep 2024 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $21K201 at $102.05 | filing |
| 20 Sep 2024filed 24 Sep 2024 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,982 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.